The progress and promise of molecular imaging probes in oncologic drug development Journal Article
| Authors: | Kelloff, G. J.; Krohn, K. A.; Larson, S. M.; Weissleder, R.; Mankoff, D. A.; Hoffman, J. M.; Link, J. M.; Guyton, K. Z.; Eckelman, W. C.; Scher, H. I.; O'Shaughnessy, J.; Cheson, B. D.; Sigman, C. C.; Tatum, J. L.; Mills, G. Q.; Sullivan, D. C.; Woodcock, J. |
| Article Title: | The progress and promise of molecular imaging probes in oncologic drug development |
| Abstract: | As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and cost-effectiveness of drug development for cancer and other diseases. Molecular imaging probes developed based on recent scientific advances have great potential as oncologic drug development tools. Basic science studies using molecular imaging probes can help to identify and characterize disease-specific targets for oncologic drug therapy. Imaging end points, based on these disease-specific biomarkers, hold great promise to better define, stratify, and enrich study groups and to provide direct biological measures of response. Imaging-based biomarkers also have promise for speeding drug evaluation by supplementing or replacing preclinical and clinical pharmacokinetic and pharmacodynamic evaluations, including target interaction and modulation. Such analyses may be particularly valuable in early comparative studies among candidates designed to interact with the same molecular target. Finally, as response biomarkers, imaging end points that characterize tumor vitality, growth, or apoptosis can also serve as early surrogates of therapy success. This article outlines the scientific basis of oncology imaging probes and presents examples of probes that could facilitate progress. The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes. © 2005 American Association for Cancer Research. |
| Keywords: | unclassified drug; review; cisplatin; fluorouracil; antineoplastic agents; ibritumomab tiuxetan; temozolomide; nuclear magnetic resonance imaging; positron emission tomography; antineoplastic agent; radiopharmaceuticals; neoplasms; cell proliferation; biological marker; dna damage; unindexed drug; apoptosis; computer assisted tomography; pharmacodynamics; breast cancer; food and drug administration; drug screening; molecular imaging; diagnostic imaging; drug design; angiogenesis; cancer research; monoclonal antibody; neuroendocrine tumor; prostate cancer; hypoxia; cost effectiveness analysis; capromab pendetide in 111; systematic review; dosimetry; daunorubicin; methoxy isobutyl isonitrile technetium tc 99m; androgen receptor; 1 fluoro 3 (2 nitro 1 imidazolyl) 2 propanol f 18; misonidazole; tumor growth; estrogen receptor; tositumomab i 131; verapamil; molecular probe; angiopeptin; biological product; multidrug resistance; radioactive material; pentetreotide in 111; colchicine; monoclonal antibody b.72.3; technology, pharmaceutical; arcitumomab tc 99m; bectumomab; bombesin tc 99m; idoxuridine; idoxuridine i 124; vapreotide; vasoactive intestinal polypeptide i 123 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 11 |
| Issue: | 22 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2005-11-15 |
| Start Page: | 7967 |
| End Page: | 7985 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-05-1302 |
| PUBMED: | 16299226 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 129" - "Export Date: 24 October 2012" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work